News | February 10, 2026
Zydus Lifesciences reports strong Q3 & 9M FY26 growth
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
The receipt of this order further strengthens the company's position in the global pharmaceutical market
Subscribe To Our Newsletter & Stay Updated
